Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica
Previous issue | Volume 64 | BES2019 | Next issue

Belgian Endocrine Society 2019

BES 2019

Endocrine consequences of immune checkpoint inhibitors

Previous section
Serum levels of Wnt-signalling parameters poorly reflect bone mass and metabolism in healthy boys and men
Table of contents
Next section
Low dose continuous IV etomidate for severe Cushing’s syndrome in the non-critical care setting: a clinical study

ea0064006 | Endocrine consequences of immune checkpoint inhibitors | BES2019

Endocrine consequences of immune checkpoint inhibitors

Chachati A-S , Potorac I , Petrossians P , Beckers A

Immune checkpoints inhibitors have fundamentally changed the management of oncologic patients. These treatments consist of monoclonal antibodies directed against CTLA-4 (cytotoxic T-lymphocyte antigen 4), PD-1 (programmed cell death protein-1) and PD-L1 (one of its ligands). By blocking these receptors or ligands, the antibodies reverse the immune tolerance induced by the cancerous cell on the T-lymphocyte and favour lymphocytic reactivation and anti-tumor activity. Immune tol...
0 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more